Apex Molecular Enhances Medicinal Chemistry Team with Dr. Jason Tierney Appointment

Apex Molecular Limited, a company within the portfolio of Catapult Ventures Group, is strategically expanding its drug discovery capabilities by appointing Dr. Jason Tierney as a medicinal chemistry consultant. Dr. Tierney, a veteran with over 25 years in drug discovery, has contributed to major pharmaceutical firms, CROs, and biotech companies with experience spanning neuroscience to rare diseases. He is noted for his work with emerging modalities including RNA therapeutics and PROTACs, and has a significant number of patents and publications to his name. Apex Molecular aims to leverage his extensive expertise to escalate their Design-Make-Test-Analysis cycles, meeting growing market demands for medicinal chemistry and enhancing their service offerings. CEO Stuart Brown highlights the anticipated opening of new business avenues and continuous company growth resulting from this appointment. Dr. Tierney shares his enthusiasm for collaborating with Apex's synthetic chemistry team to advance drug discovery projects and drive growth.